Published in Obesity and Diabetes Week, February 19th, 2007
Designed and discovered by Isis Pharmaceuticals Inc., iCo-007 is a second-generation antisense drug that targets c-Raf kinase messenger RNA. ICo-007 is expected to decrease the edema in the retina by decreasing the signaling of various growth factors such as VEGF that signal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week